Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinomaRead More
Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease SeverityRead More
Severe PATCHED1 Deficiency in Cancer-Prone Gorlin Patient Cells Results in Intrinsic RadiosensitivityRead More
Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral CenterRead More
Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease SeverityRead More
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysisRead More
Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert MeetingRead More
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc AnalysisRead More
